Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Recommended for you

Advertisements

Quick Links

Market News

Sensex sheds 499 pts; Bank of Baroda, ICICI Bank results disappoint

Coal India drops 4 per cent even as its Rs 22,000 crore offer for sale fully subscribed; Nifty sheds 143 pts

Coal India 10% stake sale fully covered

Investors bid for 662 million shares of Coal India versus the issue size of 631.6 million shares

Sensex ends below 29,200; BSE Bankex down 3%

The 30-share Sensex provisionally ended down by 482 points at 29,199 and the 50-share Nifty slipped 130 points at 8,823.

Strides Arcolab gains on USFDA OKs oral dosage facility at Bangalore

The stock was up 4% at Rs 933 on BSE.

ICICI Bank dips over 5% post Q3 results

At 1445 hours, the stock was down nearly 6% at Rs 358 on National Stock Exchange.

 

Back to Top